They are projecting Next Quarter growth of 10.3%. It increased, as 41 investors sold BSX shares while 173 reduced holdings. The fund owned 7,199,407 shares of the medical equipment provider’s stock after selling 1,061,138 shares during the period. Capital World Investors lifted its stake in Boston Scientific Corporation by 1.6% in the second quarter. HighTower Advisors LLC boosted its holdings in Boston Scientific Corporation by 17.6% in the first quarter. Bollard Group LLC now owns 33,797,061 shares of the company’s stock worth $789,837,000 after buying an additional 500,370 shares in the last quarter. Its weekly and monthly volatility is 1.63%, 1.55% respectively.
The company now has an insider ownership of 0.1 Percent and Institutional ownership of 94.3 Percent. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of USA and global trademark and copyright law. The legal version of this story can be viewed at https://stocknewstimes.com/2017/11/10/boston-partners-has-210-01-million-position-in-boston-scientific-corporation-bsx.html.
In related news, EVP Timothy A. Pratt sold 11,061 shares of the company’s stock in a transaction that occurred on Monday, October 2nd. Year to Date performance value (YTD perf) value is 32.18%. Following the completion of the sale, the executive vice president now directly owns 185,742 shares of the company’s stock, valued at $5,100,475.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The shares were sold at an average price of $27.46, for a total value of $277,455.84. The disclosure for this sale can be found here. Insiders have sold a total of 508,864 shares of company stock worth $14,581,669 in the last quarter.
Boston Scientific Corporation (NYSE:BSX) closed its last session at $28.59. However, -2.32% over the last one month, 8.25% for the last quarter and year to date performance stands at 32.18%. The company has a current ratio of 0.72, a quick ratio of 0.50 and a debt-to-equity ratio of 0.58.
E*TRADE Financial Corporation (NASDAQ:ETFC) now has a PEG ratio of 1.28 where as its P/E ratio is 20.23.
Boston Scientific Corporation (BSX) share price jumped 0.5% to $28.1 in the last trading session. The medical equipment provider reported $0.31 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.31.
More notable recent Boston Scientific Corporation (NYSE:BSX) news were published by: Prnewswire.com which released: “Boston Scientific Announces Results For Third Quarter 2017” on October 26, 2017, also Natlawreview.com with their article: “Failure to Propose Proper Hypothetical Claim Dooms Doctrine of Equivalents …” published on October 30, 2017, Prnewswire.com published: “Boston Scientific To Participate In Stifel 2017 Healthcare Conference” on November 08, 2017. During the same period in the prior year, the business earned $0.27 earnings per share.
In recent trade, Boston Scientific Corporation (NYSE:BSX) declared the eased up of 0.54% and finalized at $27.96 with the total traded volume of 4.88 Million shares.
Several analysts have commented on BSX shares. Analysts believe that we could see stock price minimum in the $24 range (lowest target price), allowing for another -16.05% drop from its current position. Canaccord Genuity began coverage on Boston Scientific Corporation in a report on Tuesday, October 24th.
The collective rating of 1.8 for Boston Scientific Corporation (NYSE:BSX) also leans strongly towards the bullish end of the spectrum. Finally, Zacks Investment Research raised Boston Scientific Corporation from a “sell” rating to a “hold” rating in a research note on Monday, July 31st. Six equities research analysts have rated the stock with a hold rating, twenty have given a buy rating and one has assigned a strong buy rating to the company.
Day traders strive to make money by exploiting minute price movements in individual assets (usually stocks, though currencies, futures, and options are traded as well), usually leveraging large amounts of capital to do so, therefore they trade on Stocks in Play.
Boston Scientific Corporation is a worldwide developer, manufacturer and marketer of minimally invasive medical devices.